FY2016 EPS Estimates for Astrazeneca PLC Cut by Analyst (AZN)
Astrazeneca PLC (NYSE:AZN) – Analysts at Jefferies Group decreased their FY2016 earnings per share (EPS) estimates for shares of Astrazeneca PLC in a research report issued on Thursday. Jefferies Group analyst J. Holford now anticipates that the brokerage will post earnings per share of $2.01 for the year, down from their prior estimate of $2.07. Jefferies Group currently has a “Buy” rating on the stock. Jefferies Group also issued estimates for Astrazeneca PLC’s FY2017 earnings at $2.03 EPS.
Astrazeneca PLC (NYSE:AZN) last issued its earnings results on Thursday, July 28th. The company reported $0.83 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.76 by $0.07. The company had revenue of $5.60 billion for the quarter, compared to analyst estimates of $5.56 billion. Astrazeneca PLC had a net margin of 9.23% and a return on equity of 28.02%. The company’s revenue for the quarter was down 4.0% on a year-over-year basis. During the same quarter last year, the firm earned $1.21 EPS.
A number of other equities research analysts have also recently issued reports on AZN. Citigroup Inc. reissued a “buy” rating on shares of Astrazeneca PLC in a research report on Saturday, June 25th. Deutsche Bank AG reaffirmed a “buy” rating on shares of Astrazeneca PLC in a research note on Monday, June 27th. Argus started coverage on Astrazeneca PLC in a research note on Tuesday, July 12th. They issued a “hold” rating for the company. Bank of America Corp. reaffirmed a “buy” rating and issued a $36.65 price target on shares of Astrazeneca PLC in a research note on Monday, July 18th. Finally, Beaufort Securities reaffirmed a “hold” rating on shares of Astrazeneca PLC in a research note on Tuesday, July 19th. Three equities research analysts have rated the stock with a sell rating, nine have issued a hold rating, ten have given a buy rating and two have issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $37.56.
Astrazeneca PLC (NYSE:AZN) opened at 30.73 on Monday. Astrazeneca PLC has a 52 week low of $26.97 and a 52 week high of $35.04. The stock has a 50 day moving average of $32.81 and a 200 day moving average of $30.93. The company has a market cap of $77.75 billion, a price-to-earnings ratio of 35.12 and a beta of 0.75.
Several institutional investors have recently bought and sold shares of AZN. Premier Asset Managment LLC raised its position in shares of Astrazeneca PLC by 83.9% in the third quarter. Premier Asset Managment LLC now owns 45,760 shares of the company’s stock worth $1,503,000 after buying an additional 20,875 shares during the last quarter. Fox Run Management L.L.C. purchased a new position in shares of Astrazeneca PLC during the third quarter worth $417,000. Atria Investments LLC purchased a new position in shares of Astrazeneca PLC during the third quarter worth $349,000. Creative Planning raised its position in shares of Astrazeneca PLC by 29.6% in the third quarter. Creative Planning now owns 36,581 shares of the company’s stock worth $1,202,000 after buying an additional 8,353 shares during the last quarter. Finally, Raymond James Trust N.A. raised its position in shares of Astrazeneca PLC by 80.9% in the third quarter. Raymond James Trust N.A. now owns 42,952 shares of the company’s stock worth $1,410,000 after buying an additional 19,209 shares during the last quarter. Hedge funds and other institutional investors own 11.46% of the company’s stock.
About Astrazeneca PLC
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Stock Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related stocks with our FREE daily email newsletter.